Therapeutic treatment
Varenzin Cat - 27ml
103134
Varenzin™-CA1 (molidustat oral suspension) is the FIRST and ONLY FDA conditionally approved option for the treatment of non-regenerative anaemia in cats with chronic kidney disease (CKD), setting the new standard of care for cats suffering from the debilitating effects of this often fatal disease.
Anaemia is caused by several factors related to kidney disease, primarily a reduction of erythropoietin (EPO), a hormone released from the kidneys that signals bone marrow to make red blood cells.
Developed exclusively for cats, Varenzin-CA1 features a mode of action that induces the genetic transcription of EPO, increasing both EPO and red blood cell production in a cat’s body.
Anaemia is caused by several factors related to kidney disease, primarily a reduction of erythropoietin (EPO), a hormone released from the kidneys that signals bone marrow to make red blood cells.
Developed exclusively for cats, Varenzin-CA1 features a mode of action that induces the genetic transcription of EPO, increasing both EPO and red blood cell production in a cat’s body.